미국의 유방암 영상 진단 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 진료 단계별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

U.S. Breast Cancer Imaging Market Summary

The U.S. breast cancer imaging market size was estimated at USD 557.88 million in 2024 and is expected to reach USD 1,012.17 million by 2033, growing at a CAGR of 7.42% from 2025 to 2033. A key factor driving market expansion is the rising prevalence of breast cancer in the country. According to Breastcancer.Org In the year 2025, approximately 316,950 women are predicted to be diagnosed with invasive breast cancer in the U.S, along with 59,080 new cases of ductal carcinoma in situ (DCIS), a non-invasive form of the disease. Furthermore, approximately 16% of breast cancer is diagnosed in women under age 50. The article states that breast cancer continues to be the most diagnosed cancer in U.S. women, with an estimated one in eight women expected to be diagnosed in their lifetime. According to American Cancer Society, the incidence has been on the rise through the years due to aging population, lifestyle opportunities, and improvements in detection. The high incidence rates, as well as high mortality rates, has fueled the demand for improving breast imaging services, including mammography, breast MRIs, and digital breast tomosynthesis (DBT), these factors are propelling growth in the market.

By enhancing early detection and access to diagnostic services, government initiatives and screening programs have significantly increased the market for breast cancer imaging in the U.S. In order to reduce the number of deaths from breast cancer, The U.S. Preventive Services Task Force (USPSTF) recommends that women aged 40 to 74 should undergo screening mammography every other year. By establishing uniform screening procedures nationwide, these recommendations ensure that more women receive imaging in a timely manner. In addition, to help with early detection and treatment, the U.S. Centers for Disease Control and Prevention (CDC)'s National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides low-income and underserved women with high-quality breast cancer screening and diagnostic services. These programs' data demonstrate that organized screening campaigns improve patient outcomes, enable earlier diagnosis, and boost adherence to suggested imaging schedules, facilitates earlier diagnosis, and improves patient outcomes. Consequently, government-endorsed screening programs expand access to advanced imaging technologies such as digital mammography, breast MRI, and digital breast tomosynthesis (DBT), thereby driving growth in the U.S. Breast Cancer Imaging market.

The expansion of imaging centers and diagnostic networks is playing a crucial role in the growth of U.S. breast cancer imaging market. Typically, imaging centers are outpatient establishments; some are privately owned, while others are run by healthcare systems or hospitals. These facilities frequently employ radiologists and doctors who diagnose and treat diseases using medical imaging, guaranteeing skilled interpretation of diagnostic tests.

Recent data provided by DEFINITIVE HEALTHCARE as of January 2025 indicates that there are approximately 15,000 imaging centers in the U.S., allowing for widespread access to breast cancer diagnostic services. The Midwest, Northeast, West and Southwest have more imaging centers compared to the Southeast This widespread geographic coverage makes it easier for patients to access important services like mammography, breast MRI, and ultrasound. It also helps with early detection and cell monitoring of patients. The growth and expansion of these centers emphasize the importance of growing diagnostic networks, which improve access for patients in various regions to screening and diagnostic capabilities, and address the growing imaging needs for breast cancer.

U.S. Breast Cancer Imaging Market Report Segmentation

This report forecasts revenue growth at the country level and analyzes the latest industry trends in each sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. breast cancer imaging market report based on technology, stage of care and end-use:

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Mammography System (2D,3D)
• Magnetic Resonance Imaging (MRI)-based systems
• Nuclear Medicine- Based Systems
• Ultrasound-Based Systems
• Image-guided Biopsy
• Others
• Stage of Care Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostics
• Pre-treatment Planning
• Monitoring
• Surveillance (Follow-Up)
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Imaging Centers
• Breast Care Centers
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Stage of Care
  • 1.2.3. End-use
• 1.3. Estimates and forecasts timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased database
  • 1.5.2. GVR's internal database
  • 1.5.3. Secondary sources
  • 1.5.4. Primary research
  • 1.5.5. Details of primary research
• 1.6. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity flow analysis (Model 1)
  • 1.8.2. Approach 1: Commodity flow approach
  • 1.8.3. Volume price analysis (Model 2)
  • 1.8.4. Approach 2: Volume price analysis
• 1.9. List of Secondary Sources
• 1.10. List of Primary Sources
• 1.11. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology
  • 2.2.2. Stage of Care
  • 2.2.3. End-use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Breast Cancer Imaging Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of breast cancer
    • 3.2.1.2. Government initiatives and screening programs
    • 3.2.1.3. Expansion of imaging centers
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Equipment Costs
    • 3.2.2.2. Maintenance costs
• 3.3. Breast Cancer Imaging Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape
• 3.4. Breast Cancer Imaging Market: Number of Procedures
• 3.5. Breast Cancer Imaging Market: Average Procedure Pricing

Chapter 4. U.S. Breast Cancer Imaging Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Breast Cancer Imaging Market: Technology Movement Analysis
• 4.3. Breast Cancer Imaging Market by Technology Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Mammography System (2D,3D)
  • 4.5.1. Mammography System (2D,3D) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Magnetic Resonance Imaging (MRI)-based Systems
  • 4.6.1. Magnetic Resonance Imaging (MRI)-based Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Nuclear Medicine- Based Systems
  • 4.7.1. Nuclear Medicine-Based Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Ultrasound-Based Systems
  • 4.8.1. Ultrasound-Based Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Ultrasound-Based Systems
  • 4.9.1. Ultrasound-Based Systems Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.10. Others
  • 4.10.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Breast Cancer Imaging Market: Stage of Care Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Breast Cancer Imaging Market: Stage of Care Movement Analysis
• 5.3. Breast Cancer Imaging Market by Stage of Care Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Diagnostics
  • 5.5.1. Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Pre-treatment Planning
  • 5.6.1. Pre-treatment Planning Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Monitoring
  • 5.7.1. Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Surveillance (Follow-Up)
  • 5.8.1. Surveillance (Follow-Up) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Breast Cancer Imaging Market: End-use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Breast Cancer Imaging Market: End-use Movement Analysis
• 6.3. Breast Cancer Imaging Market by End-use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Hospitals
  • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Diagnostic Imaging Centers
  • 6.6.1. Diagnostic Imaging Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Breast Care Centers
  • 6.7.1. Breast Care Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. Holigic, Inc.
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. GE Healthcare
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Siemens Healthineers
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Seno Medical
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. b-rayZ
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Analogic Corporation
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Icad, Inc
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Clairity, Inc.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Fujifilm
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. FONAR Corporation
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives